Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Opinion
  • Published:

Antifibrotic therapies—emerging biomarkers as treatment end points

Nature Reviews Gastroenterology & Hepatology volume 7, pages 59–61 (2010)Cite this article

Subjects

Abstract

The emergence of novel pharmacologic therapies for hepatic fibrosis holds promise for the management of this condition. Furthermore, novel, biological indices—in addition to liver biopsy—may improve our ability to assess the unique pharmacological effects generated by these agents. This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ghiassi-Nejad, Z. & Friedman, S. L. Advances in antifibrotic therapy. Expert Rev. Gastroenterol. Hepatol. 2, 803–816 (2008).

    Article  PubMed Central  Google Scholar 

  2. Friedman, S. L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J. Biol. Chem. 275, 2247–2250 (2000).

    Article  CAS  Google Scholar 

  3. Shiratori, Y. et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 132, 517–524 (2000).

    Article  CAS  Google Scholar 

  4. Bedossa, P. & Carrat, F. Liver biopsy: the best, not the gold standard. J. Hepatol. 50, 1–3 (2009).

    Article  Google Scholar 

  5. Manning, D. S. & Afdhal, N. H. Diagnosis and quantitation of fibrosis. Gastroenterology 134, 1670–1681 (2008).

    Article  CAS  Google Scholar 

  6. Fontana, R. J. et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin. Gastroenterol. Hepatol. 7, 219–226 (2009).

    Article  CAS  PubMed Central  Google Scholar 

  7. Talwalkar, J. A. et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 47, 332–342 (2008).

    Article  PubMed Central  Google Scholar 

  8. Lim, A. K. et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 54, 128–133 (2005).

    Article  CAS  PubMed Central  Google Scholar 

  9. Castera, L., Forns, X. & Alberti, A. Non-invasive evaluation of liver fibrosis using transient elastography. J. Hepatol. 48, 835–847 (2008).

    Article  Google Scholar 

  10. Talwalkar, J. A., Kurtz, D. M., Schoenleber, S. J., West, C. P. & Montori, V. M. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 5, 1214–1220 (2007).

    Article  Google Scholar 

  11. Yin, M. et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin. Gastroenterol. Hepatol. 5, 1207–1213 (2007).

    Article  PubMed Central  Google Scholar 

  12. Huwart, L. et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135, 32–40 (2008).

    Article  Google Scholar 

  13. Vizzutti, F., Arena, U., Marra, F. & Pinzani, M. Elastography for the non-invasive assessment of liver disease: limitations and future developments. Gut 58, 157–160 (2009).

    Article  PubMed Central  Google Scholar 

  14. Girometti, R. et al. Relevance of b-values in evaluating liver fibrosis: a study in healthy and cirrhotic subjects using two single-shot spin-echo echo-planar diffusion-weighted sequences. J. Magn. Reson. Imaging 28, 411–419 (2008).

    Article  Google Scholar 

  15. Strijbos, M. H. et al. Circulating endothelial cells in oncology: pitfalls and promises. Br. J. Cancer 98, 1731–1735 (2008).

    Article  CAS  PubMed Central  Google Scholar 

  16. Boos, C. J., Lip, G. Y. & Blann, A. D. Circulating endothelial cells in cardiovascular disease. J. Am. Coll. Cardiol. 48, 1538–1547 (2006).

    Article  CAS  Google Scholar 

  17. Dome, B. et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 66, 7341–7347 (2006).

    Article  CAS  Google Scholar 

  18. Corretti, M. C. et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 39, 257–265 (2002).

    Article  Google Scholar 

  19. Wright, S. A. et al. A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Ann. Rheum. Dis. 67, 841–848 (2008).

    Article  CAS  Google Scholar 

  20. Chong, A. Y. et al. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110, 1794–1798 (2004).

    Article  Google Scholar 

  21. Fernández, M. et al. Angiogenesis in liver disease. J. Hepatol. 50, 604–620 (2009).

    Article  Google Scholar 

  22. Assy, N., Paizi, M., Gaitini, D., Baruch, Y. & Spira, G. Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. World J. Gastroenterol. 5, 296–300 (1999).

    PubMed  Google Scholar 

  23. O'Connor, J. P., Jackson, A., Parker, G. J. & Jayson, G. C. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer 96, 189–195 (2007).

    Article  CAS  PubMed Central  Google Scholar 

  24. Textor, S. C. et al. The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. J. Am. Soc. Nephrol. 19, 780–788 (2008).

    Article  PubMed Central  Google Scholar 

  25. Diab, D. L. et al. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin. Gastroenterol. Hepatol. 6, 1249–1254 (2008).

    Article  CAS  PubMed Central  Google Scholar 

  26. Blankenberg, F. G. In vivo detection of apoptosis. J. Nucl. Med. 49 (Suppl. 2), 81S–95S (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Advanced Imaging Research, Miles and Shirley Fiterman Center for Digestive Diseases, Mayo Clinic, 200 First Street S. W., Rochester, 55905, MN, USA

    Jayant A. Talwalkar

Authors
  1. Jayant A. Talwalkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares that he receives grant/research support from Salix and Merck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talwalkar, J. Antifibrotic therapies—emerging biomarkers as treatment end points. Nat Rev Gastroenterol Hepatol 7, 59–61 (2010). https://doi.org/10.1038/nrgastro.2009.197

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2009.197

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research